Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Harmony Biosciences Holdings, Inc. (HRMY) announced a planned leadership transition: President and CEO Jeffrey M. Dayno, M.D., will retire and step down as a Class I director effective December 31, 2026, at 11:59 p.m. Eastern Time, and will serve as a non-executive advisor through 2027. The Board appointed current Chief Operating Officer Peter Anastasiou as President and CEO and a Class I director effective January 1, 2027, at 12:00 a.m. Eastern Time; his director term runs until the 2027 Annual Meeting of Stockholders. Anastasiou has served as COO since April 2026 and previously served on Harmony’s Board from November 2023 to April 2026.
Harmony reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion. The company said it remains on track to report data from the BP-205 multiple ascending dose (MAD) study in Q4 2026 and does not currently expect a change in the timing of key commercial and pipeline milestones. Its stated priorities include growing the pitolisant franchise, advancing its CNS pipeline led by BP-205, strategic capital deployment and protecting WAKIX exclusivity.
Harmony Biosciences Holdings, Inc. (HRMY) reported that its Chief Medical Officer, Kumar Budur, exercised stock options and sold shares over September 16–18, 2026. He exercised options covering 38,452 shares of Common Stock at exercise prices of $30.69 and $30.27, then sold 38,452 shares in open-market transactions at weighted average prices around $43 per share pursuant to a Rule 10b5-1 trading plan.
Harmony Biosciences Holdings, Inc. (HRMY) officer Kumar Budur filed a notice of proposed resale of 35,852 shares of common stock under Rule 144, to be sold through Morgan Stanley Smith Barney LLC, with an indicated market value of $1,532,314.48 and based on 58,236,393 shares outstanding on NASDAQ as of September 18, 2026.
The shares are to be sold on September 18, 2026 following an exercise of stock options for cash. Over the prior three months, Budur reported multiple Rule 10b5-1 plan sales of HRMY common stock, including blocks of 800, 1,800, 5,500, 22,954, and 5,500 shares on various September 2026 dates.
Harmony Biosciences Holdings, Inc. (HRMY) received a notice under Rule 144 from officer Kumar Budur of a proposed sale of 800 shares of common stock, expected on September 17, 2026, following an exercise of stock options for cash through Morgan Stanley Smith Barney LLC on Nasdaq.
The notice states an aggregate market value for the proposed sale of about $33,768, with 58,236,000 shares outstanding. It also lists prior Rule 10b5-1 plan sales by Budur in the past three months totaling several blocks of common shares between September 4 and September 16, 2026.
Harmony Biosciences Holdings, Inc. (HRMY) has an officer, Kumar Budur, filing a notice of proposed sale of restricted or control securities under Rule 144. The filing covers up to 1,800 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on September 16, 2026, in connection with a cash exercise of stock options.
The filing also lists prior Rule 10b5-1 sales of common stock by Kumar Budur during the preceding three months, including separate transactions of 5,500 shares, 22,954 shares, and 5,500 shares on September 8 and September 4, 2026, respectively, with stated aggregate sale proceeds for each transaction.
Harmony Biosciences Holdings, Inc. (HRMY) reported that Chief Medical Officer Kumar Budur exercised stock options for a total of 22,954 shares of common stock on September 8, 2026, at exercise prices of $30.69 and $30.27 per share. On September 4 and 8, 2026, he sold an aggregate of 33,954 shares of common stock in open-market transactions at weighted average prices between approximately $41.51 and $43.20 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan.
Harmony Biosciences Holdings, Inc. (HRMY) received a Rule 144 notice from officer Kumar Budur covering the proposed sale of up to 28,454 shares of common stock through Morgan Stanley Smith Barney LLC. The shares have an aggregate market value of $1,202,181.50 and are listed on NASDAQ, with 58,236,393 shares outstanding as of September 8, 2026.
The shares to be sold were acquired from vested restricted stock units between January 24, 2025 and January 25, 2026, from the employee stock purchase plan on November 30, 2022 and May 31, 2023, and from the exercise of stock options on September 8, 2026. In the prior three months, Budur reported a 10b5-1 sale of 5,500 shares for proceeds of $230,911.45.
Harmony Biosciences Holdings, Inc. (HRMY) received a Rule 144 notice from executive Kumar Budur covering the proposed sale of 5,500 shares of common stock through Morgan Stanley Smith Barney. The shares were acquired from vesting restricted stock units between January 24, 2025 and January 25, 2026.
Harmony Biosciences shareholder VALOR IV PHARMA HOLDINGS LLC filed to sell up to 700,883 shares of common stock, which were acquired on 10/06/2017 through a Private Acquisition from Issuer/Affiliate for cash. The class of common stock has an aggregate market value of $26,563,465.70 and 58,236,393 shares outstanding as of 08/07/2026 on NASDAQ; this is a baseline figure, not the amount being sold. The filing also lists prior sales over the past three months totaling 116,490 shares for approximately $4,332,549.00.
Harmony Biosciences Holdings, Inc. reported higher profitability for Q2 2026, with net product revenue of 261,280 (in thousands) versus 200,489 a year earlier and net income of 75,431 versus 39,776. Diluted earnings per share were 1.28 compared with 0.68.
For the first six months of 2026, net product revenue reached 476,667 and net income was 107,919. Operating cash flow was 120,192, and cash, cash equivalents and investments totaled 962,459 as of June 30, 2026; the company states this should meet operational needs for at least twelve months. Long-term debt principal outstanding was 155,000.
WAKIX remains the only commercial product, while the pipeline includes a Phase 3 Prader–Willi syndrome study and new pitolisant formulations. An NDA for Pitolisant GR has been accepted with a PDUFA date of April 1, 2027. The company has settled several generic WAKIX ANDA actions with licensed entry generally around 2030, while other patent and antitrust-related proceedings continue.